Comparison chart: SGLT2 inhibitors.
出版信息
Med Lett Drugs Ther. 2020 Nov 16;62(1611):e2-e4.
PMID:33429417
Abstract
摘要
相似文献
1
Comparison chart: SGLT2 inhibitors.
Med Lett Drugs Ther. 2020 Nov 16;62(1611):e2-e4.
2
Ertugliflozin for type 2 diabetes.
Med Lett Drugs Ther. 2018 Apr 23;60(1545):70-72.
3
Drugs for type 2 diabetes.
Med Lett Drugs Ther. 2019 Nov 4;61(1584):169-178.
4
Drugs for type 2 diabetes.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):177-184.
5
Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
Med Lett Drugs Ther. 2018 Mar 26;60(1543):55-56.
6
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.
Med Lett Drugs Ther. 2019 Feb 25;61(1566):26-28.
7
In brief: Canagliflozin and lower limb amputations.
Med Lett Drugs Ther. 2020 Sep 21;62(1607):152.
8
Sotagliflozin (Inpefa) for heart failure.
Med Lett Drugs Ther. 2023 Jul 24;65(1681):114-116. doi: 10.58347/tml.2023.1681b.
9
Bexagliflozin (Brenzavvy) - A fifth SGLT2 inhibitor for type 2 diabetes.
Med Lett Drugs Ther. 2023 Aug 21;65(1683):130-132. doi: 10.58347/tml.2023.1683b.
10
Empagliflozin (Jardiance) for heart failure.
Med Lett Drugs Ther. 2020 Nov 16;62(1611):177-178.
Zotero 插件